Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

Shots:

• The P-II NURTURE study involves assessing of Spinraza in comparison to the natural history of the disease in 25 pre-symptomatic infants with SMA
• The P-II NURTURE study resulted in achieving motor milestones including 100% of children sitting without support & 88% walking independently. The results support long-term safety & efficacy of Spinraza demonstrating continuous improvement in attaining motor milestones
• Spinraza is a disease-modifying & an approved therapy for treating infants, children and adults with SMA, currently available in 40+ countries, being evaluated in a SHINE extension study of children with infantile and later-onset SMA as well the CS2/CS12 analysis of older patients

Click here to read full press release/ article | Ref: Biogen | Image: The Business Journals